Astellas Pharma Inc.

ALPMF | OTC

Price Alert Chart Builder DCF Calculator

$15.25

+$1.40 (+10.11%)

At close: Sep 21, 2026, 3:47 PM ET

$15.25

$0 (0.00%)

After-hours: Sep 21, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

+10.11%

(1D)

Rating

Updated: Sep 15, 2026

7.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $27.32B

1D Range

15.25 15.25

52W Range

9.85 17.85

Valuation (TTM)

PE 50.94

PB 2.65

EV/EBITDA 9.85

Valuation (NTM)

Forward PE 12.03

Forward PEG 12.09

Price Target N/A

Cash Flow

FCF Yield 4.7%

SBC Adj. FCF Yield 4.7%

SBC Impact N/A

Margins

Gross Margin 74.7%

Operating Margin 5.4%

FCF Margin 10.3%

Growth (CAGR)

Revenue 3Y | 5Y 12.9% | 8.8%

Dil EPS 3Y | 5Y -11.3% | -14.9%

FCF 3Y | 5Y 1.6% | 8.2%

Returns

ROA 9.9%

ROE 20.4%

ROIC 14.0%

Financial Health

Net Debt

¥674.09B ($4.68B)

Current Ratio 1.20

Interest Coverage 43.91

Dividends

Div Yield 3.34%

Payout Ratio 1.1%

FCF Payout Ratio 65.9%

All Key Statistics

Loading financial charts...

Profile

A detailed description of the company is not yet available.

Sector n/a

Industry n/a

Employees n/a

IPO Date n/a

Website n/a

Fiscal Year n/a

Full Company Profile

Latest News

1 month ago · seekingalpha.com

Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors

The portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata Manufacturing, SoftBank Group and Astellas Pharma.

Earnings

Next Earnings

Nov 4, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞